Cigna Now Covering Avedro’s FDA-Approved Cross-Linking Procedure

Source: Avedro

Avedro announced that 50 commercial insurance plans now cover Avedro’s FDA-approved corneal cross-linking procedure, following Cigna’s recent announcement that it is covering the Photrexa drug formulations and the KXL System used in the treatment of progressive keratoconus. Other health plans recently initiating coverage include Humana, Blue Cross Blue Shield of Florida, Capital Blue Cross of Central Pennsylvania, Health Alliance Plan of Michigan, Blue Cross Blue Shield of Minnesota, Blue Cross Blue Shield of North Dakota and Priority Health of Michigan.

These recent positive decisions added nearly 35 million beneficiaries across all 50 states bringing the total number of covered lives to 133 million. Patients can find an updated list of plans with positive coverage policies at LivingwithKeratoconus.com.

“In the past year, market access to FDA-approved corneal cross-linking has increased substantially. We have enjoyed collaborating with the ophthalmology societies and Avedro on this effort,” Mary Prudden, Director of the National Keratoconus Foundation, said in a company news release. “This encouraging progress will tremendously help patients who are struggling with progressive keratoconus, a sight-threatening disease.”

In a continued effort to expand market access and reimbursement for cross-linking, Avedro also announced that Tim Homer joined the company as Vice President of Health Policy & Market Access. Mr. Homer will lead Avedro’s health policy, reimbursement and government relations activities.

“Tim brings critical expertise to Avedro at an exciting time in our company’s history,” Reza Zadno, PhD, CEO of Avedro, said in the news release. “We are particularly pleased with the momentum we are seeing among commercial payers and CMS’ preliminary decision to grant a product-specific J code for our Photrexa drug formulations. Working closely with our executive leadership team, Tim will lead our efforts to broadly communicate the value of corneal cross-linking.”

Mr. Homer’s first initiative has been to expand ARCH (Avedro’s Reimbursement Customer Hub) services, including establishing a new field-based team to educate physician offices and payers and ultimately expand patient access to cross-linking.

Mr. Homer has more than 20 years of medical device and health policy experience. Previously, Mr. Homer worked at IRhythm as Vice President of Health Policy and Market Access where he was instrumental in helping grow revenue to more than $100 ,illion. Prior to IRhythm, Mr. Homer led global reimbursement and market access activities at HeartWare and additionally, worked in similar capacities at Boston Scientific and Johnson & Johnson.

Related Content